Related Experiment Video
Updated: Jan 10, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.1K
Metformin and Myo-Inositol: A Comparative Analysis
Michele Russo1, Mario Montanino Oliva2,3, Maurizio Nordio2,4
1R&D Department, Lo.Li pharma s.r.l, Rome, Italy.
Gynecologic and Obstetric Investigation
|November 21, 2025
Summary
Myo-inositol offers a safer profile than metformin for polycystic ovary syndrome (PCOS) and other conditions. While both are studied for fertility, myo-inositol shows higher tolerance, unlike metformin
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
- Nutraceutical Science
Background:
- Metformin and myo-inositol are key treatments for polycystic ovary syndrome (PCOS) endocrine-metabolic issues.
- Myo-inositol is explored as a nutraceutical alternative to metformin.
- Both compounds have distinct mechanisms and potential applications beyond PCOS.
Purpose of the Study:
- To contrast metformin and myo-inositol regarding their mechanisms of action.
- To compare adverse effects and safety profiles.
- To explore novel indications for both compounds.
Main Methods:
- A narrative review was conducted.
- Literature search performed on PubMed, Google Scholar, and Web of Science.
- Data collection occurred between August and November 2024.
Main Results:
- Myo-inositol exhibits a superior safety profile compared to metformin, which can cause gastrointestinal issues and lactic acidosis.
- Myo-inositol is a naturally occurring molecule with diverse biological roles, distinct from metformin's pharmacological action.
- Both agents show promise in gynecology for improving fertility and pregnancy outcomes, but metformin's use in pregnancy remains controversial.
Conclusions:
- Myo-inositol demonstrates high tolerance, whereas metformin's safety in pregnancy is debated.
- Further research is needed to elucidate the potential of myo-inositol and metformin in mental health and oncology.
- Understanding the unique properties of each molecule is crucial for targeted therapeutic applications.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
01:17Equivalence: In Vitro and In Vivo Bioequivalence
200
Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
200
01:23Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
139
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
139
01:17Oral Hypoglycemic Agents: Sulfonylureas
733
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
733